The FDA approved ribocilib (Kisqali; Novartis) with an aromatase inhibitor (AI) for breast cancer patients with HR-positive, HER2-negative stage II and III early breast cancer at high risk of ...
Search for other works by this author on: ...
This open access article is distributed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0) license. This work is licensed under a Creative Commons ...
Department of Medical Oncology, Dana Farber Cancer Institute, Boston, Massachusetts.
Search for other works by this author on: ...
Search for other works by this author on: ...
University of Nebraska Medical Center, Omaha, NE, ...
Department of Hematology and Medical Oncology, Emory University School of Medicine, Atlanta, Georgia.
Division of Cell Signaling and Metabolism, German Cancer Research Center (DKFZ) and DKFZ-ZMBH Alliance, Heidelberg, Germany.
Adding the PD-1 inhibitor pembrolizumab to chemoradiotherapy for high-risk, locally advanced cervical cancer significantly improves patients’ overall survival compared to treatment with CRT alone.
Program of Immunology and Immunotherapy, Cima Universidad de Navarra, Pamplona, Spain.
Two HER2-targeted tyrosine kinase inhibitors, BAY 29270078 and zongertinib, each showed robust efficacy and safety in early phase. Patients experienced significant tumor shrinkage rates, and the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback